ArticleJournal of molecular medicine (Berlin, Germany)2025
Role of endosomal RANKL-LGR4 signaling during osteoclast differentiation.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recombinant LGR4 extracellular domain attenuates osteoclastogenesis and prevents bone metastasis via RANKL inhibition.Journal of bone oncology · 2026Article
- Cell signaling and transcriptional regulation of osteoclast lineage commitment, differentiation, bone resorption and diseases.Cell discovery · 2026Review
- Generation and Purification of RANKL-Derived Small-Fragment Variants for Osteoclast Inhibition.Pharmaceutics · 2025Article
- Mechanical control of osteoclast fusion by membrane-cortex attachment and BAR proteins.The Journal of cell biology · 2025Article
- The role of LGR4 in bone metabolism and tumor bone metastasis.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4, also known as GPR48) is a membrane receptor that negatively regulates the RANK signaling cascade during osteoclastogenesis. Traditionally, cell signaling and endocytic membrane trafficking via membrane receptors have been considered distinct processes; however, they are now recognized to be closely and bidirectionally linked. The present study investigated the difference between membrane-bound and endosomal LGR4 signaling and whether the LGR4 signaling pathway influences RANK-RANKL signaling during RANKL-induced osteoclastogenesis. We used CRISPR-Cas9 to create LGR4 conditional knock-out (CKO) in RAW 264.7 cells and Drg2 knockout (KO) in mice to study the impacts of LGR4 and DRG2 on osteoclastogenesis. LGR4 was endocytosed into endosomes after binding to RANKL in RAW 264.7 s osteoclast precursor cells. Within the early endosomes, internalized LGR4 activates LGR4-RANKL signaling. When bound to RANKL, LGR4 is endocytosed and localized in the RAB5-positive endosomes. In Lgr4 CKO RAW 264.7 cells, early endosome signaling was increased and the inhibitory phosphorylation of GSK-3β was decreased, both in the whole lysate and endosome fraction. RANKL treatment increased nuclear translocation of NFATC1 in Lgr4 CKO RAW 264.7 cells and Drg2 KO mice. Overall, our results suggested that RANKL-LGR4 signaling is regulated by membrane-to-endosomal trafficking during osteoclastogenesis. KEY MESSAGES: Bone resorption by osteoclasts is essential for bone homeostasis and remodeling. However, the mechanisms underlying the regulation of osteoclastogenesis are not yet fully understood. The present study investigated the difference between membrane-bound and endosomal LGR4 signaling, and whether the LGR4 signaling pathway influences RANK-RANKL signaling during RANKL-induced osteoclastogenesis. Our results suggested that RANKL-LGR4 signaling is regulated by membrane-to-endosomal trafficking during osteoclastogenesis.
Indexed as
Identifiers
39954074What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.